## **Supplementary Material**

## **Opioid dispensing 2008–18: a Queensland perspective**

*Benita Suckling*<sup>A,B,\*</sup>(BPharm, GDipClinPharm, Medicines Safety Pharmacist), *Champika Pattullo*<sup>C</sup> (BPharm, GCert Health Service Innovation, Quality Use of Medicines Pharmacist), *Peter Donovan*<sup>C</sup> (FRACP, Director of Clinical Pharmacology), *Marcus Gallagher*<sup>D</sup> (PhD, Associate Professor), *Asad Patanwala*<sup>A,E</sup> (PharmD, MPH, Professor) and *Jonathan Penm*<sup>A,F</sup> (PhD, Senior Lecturer & Pharmacist)

<sup>A</sup>School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

<sup>B</sup>Caboolture Hospital Pharmacy Department, Metro North Health, Queensland Health, Brisbane, Qld, Australia

<sup>C</sup>Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Queensland Health, Brisbane, Qld, Australia

<sup>D</sup>School of Information Technology and Electrical Engineering, The University of Queensland, Brisbane, Qld, Australia

<sup>E</sup>Department of Pharmacy, Royal Prince Alfred Hospital, Camperdown, NSW, Australia

<sup>F</sup>Department of Pharmacy, Prince of Wales Hospital, Randwick, NSW, Australia

\*Correspondence to: Email: <u>benita.suckling@health.qld.gov.au</u>

Supplementary Material File S1– Data excluded from analysis

Data received from the Department of Health was filtered to exclude the following non-opioid controlled drugs, injectable dosage forms, fentanyl lozenges and opioid preparations listed as products used in an opioid treatment program, including certain buprenorphine and methadone products. These were excluded as indications for such products or routes are not the target of opioid stewardship strategies and their potency has the potential to misrepresent and inflate the intended data.

Excluded data:

Non-opioid controlled drugs (Schedule 8)
Alprazolam (all strengths and forms)
Cocaine (all strengths and forms)
Dexamphetamine (all strengths and forms)
Flunitrazepam (all strengths and forms)
Ketamine (all strengths and forms)
Lisdexamfetamine (all strengths and forms)
Medicinal Cannabis (all strengths and forms)
Methylphenidate (all strengths and forms)
Injectable and other excluded dosage forms
Alfentanil 1mg/2mL ampoule
Buprenorphine 0.3mg/mL ampoule
Fentanyl ampoule (all strengths)
Fentanyl + local anaesthetic combinations (all strengths)
Fentanyl lozenge (all strengths)
Fentanyl buccal tablet (all strengths)
Morphine ampoule (all strengths)
Oxycodone ampoule (all strengths)
Pethidine ampoule (all strengths)
Remifentanil ampoule (all strengths)
Sufentanil (all strengths)
Products used primarily in an opioid treatment program
Methadone hydrochloride syrup 5mg/mL
Buprenorphine sublingual 0.4mg tablet
Buprenorphine sublingual 1mg tablet
Buprenorphine sublingual 2mg tablet
Buprenorphine sublingual 8mg tablet
Buprenorphine + naloxone sublingual films (all strengths)